3 research outputs found
Prevalence of abnormal cervical cytology and HPV DNA positivity among HIV positive women
Background: The relationship among HIV, HPV, and development of CIN is complex and incompletely understood. Present study is undertaken to find out the prevalence and relationship of abnormal cervical cytology and HPV infection in HIV positive women.Methods: This was a cross-sectional, case control study conducted on 95 HIV seropositive and 95 seronegative women. Specimen was collected from the cervix for HPV DNA testing, subtyping and cytology.Results: HPV DNA positivity was higher in seropositive group (18.6% vs. 7.4%). Premalignant conditions were found only in seropositive group. At CD4 count 500 HPV DNA positivity was 19%.Conclusions: Prevalence of abnormal cytology and HPV DNA positivity is higher amongst HIV positive women and there is an association between HPV DNA positivity with lower CD4 counts.
A comprehensive mechanistic basis of prostate cancer advancement & its personalized implementation-bridging the gap: present state and future prospect
Despite significant achievements in prostate cancer mechanistic understanding
and its targeted therapies, currently there exists several major challenges that
mainly arises during the therapy of advanced prostate cancer. Present prostate
cancer precision medicine strategy principally suffers from several practical
concerns, particularly in point of therapeutic resistance, tumor heterogeneity,
complex clinical & pathological behavior and an extensive genomic perturbation
landscape.
Prostate Cancer Systems-Medicine Initiative is a global
trans-disciplinary movement taken from corresponding scientific domains to
critically determine the nature of this major existing challenges and its
corresponding most possible solutions by systematically accumulating the present
existing knowledge. Basically, it explains the importance of broad spectrum
cancer hallmark based integrative approaches for development of combination
therapy associated strategic measures for metastatic castration resistant
prostate cancer. The major findings of this initiative can be summarized by
identification of 136 therapeutic resistance mediators, 103 prostate cancer
driver oncogenes and 8 progression pathways along with 5 terrain factors which
centrally drives the basic events in prostate cancer pathogenesis, its further
metastatic propagation and ultimate therapeutic resistance. In addition, it also
attempts to summarize the critical features and basic challenging aspects of
current therapeutic options